Mind the (Gender) Gap: Does Prolactin Exert Gender and/or Site-Specific Effects on the Human Hair Follicle?  by Langan, Ewan A. et al.
Mind the (Gender) Gap: Does Prolactin Exert
Gender and/or Site-Specific Effects on the
Human Hair Follicle?
Journal of Investigative Dermatology (2010) 130, 886–891; doi:10.1038/jid.2009.340; published online 5 November 2009
TO THE EDITOR
The pleiotropic, cytokine-like polypep-
tide neurohormone prolactin (PRL),
primarily produced by the pituitary
gland, is most widely appreciated for
its central role in the regulation of
lactation and reproduction. How-
ever, PRL is important in a bewildering
array of biological processes spanning
growth and development, immunore-
gulation, osmoregulation, metabolism,
and the stress response (Ben-Jonathan
et al., 1996, 2008; Bole-Feysot et al.,
1998; Freeman et al., 2000; Grattan
and Kokay, 2008). The importance of
PRL in cutaneous biology and patho-
logy was first postulated almost two
decades ago (Paus, 1991), and interest
in its role in skin biology has recently
been revived (Foitzik et al., 2009).
Prolactin has been implicated in the
pathogenesis of several inflammatory
dermatoses, including psoriasis (Gia-
suddin et al., 1998) and acne vulgaris
(Davidovici et al., 2008), and systemic
diseases with cutaneous manifestations,
including rheumatoid arthritis (Velke-
niers et al., 1998), systemic lupus
erythematosus (De Bellis et al., 2005),
systemic sclerosis (Shahin et al., 2002),
and Behcet’s disease (Proenc¸a et al.,
2007). Moreover, both mouse and
human skin have been identified as
nonclassical, extrapituitary sites of PRL
expression, which also respond to PRL
receptor (PRLR)-mediated signaling, for
example, with changes in hair growth
and hair keratinocyte proliferation in
situ (Craven et al., 2001; Foitzik et al.,
2003, 2006, 2009). This is not surpris-
ing given that the regulatory effects
of PRL on hair growth, in several
species, have been documented for
over 20 years (see Foitzik et al., 2009
for review).
However, more detailed analysis of
the regulatory effects of PRL on hair
growth reveals surprising and at times
seemingly contradictory, inter- and
intraspecies variations in the hair folli-
cle (HF) response to PRL (Table 1).
Murine skin and human scalp HFs
express both PRL and functional PRLR
at the gene and protein levels, and PRL
operates as a potent modulator of
HF cycling (Craven et al., 2001, 2006;
Foitzik et al., 2003, 2006). In mice,
PRL appears to operate primarily as a
potent hair growth inhibitor; it induces
premature catagen development and
hair matrix keratinocyte apoptosis, and
inhibits hair matrix keratinocyte
proliferation in skin organ culture of
back skin pelage follicles, whereas
PRLR knockout mice have longer and
coarser hair than wild-type controls
(Craven et al., 2001, 2006; Foitzik
et al., 2003).
HAIR GROWTH MODULATION
BY PRL: A CONFUSING PICTURE
Interestingly, administration of bromo-
criptine, a dopaminergic inhibitor of
pituitary PRL secretion, induces telogen
effluvium in women (Fabre et al.,
1993), but not in men. This is likely to
be due to premature catagen induc-
tion. This raises the possibility that, in
women, PRL may actually be a hair-
growth-promoting/anagen-maintaining
factor.
The predominantly hair-growth-inhi-
bitory effect seen in (female) mice is
recapitulated in the serum-free organ
culture of human HFs (Lu et al., 2007;
Philpott et al., 1990): high-dose PRL
(400 ng ml1, a level that can be found
in patients with macroprolactinoma)
stimulated premature catagen develop-
ment and inhibited hair shaft produc-
tion and hair matrix keratinocyte
proliferation in microdissected HFs
from male occipital scalp skin (Foitzik
et al., 2006).
Thus, we were surprised to find
that, in a repeat HF organ culture
experiment, using a small number of
HFs derived from female frontotempor-
al scalp skin, the same dose of PRL
(400 ng ml1) resulted in significant
HF shaft elongation. Therefore, we
repeated these experiments with a
larger number of female HFs, derived
from frontotemporal scalp skin speci-
mens from additional donors, used a
well-characterized specific PRLR an-
tagonist (Goffin et al., 2005), assessed
PRLR expression immunohistologically,
and used microarray technology to
examine the modulation of intrafollicu-
larly expressed genes.
In these repeat analyses, PRL treat-
ment (400 ng ml1) of female fronto-
temporal scalp HFs again significantly
promoted hair shaft elongation in
serum-free HF organ culture. This effect
was reduced in the presence of a pure
PRLR antagonist (del1-9-G129R-hPRL,
4 mg ml1) (Bernichtein et al., 2003;
Figure 1a). In contrast to the prominent
catagen-inducing effects seen in male
occipital scalp HFs (Foitzik et al.,
2006), PRL did not have such an effect
in female frontotemporal HFs. More-
over, treatment with PRLR antagonist
alone significantly inhibited both HF
hair shaft production (Figure 1b) and
spontaneous catagen development
(Figure 1c). This catagen-promoting effect
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of the used PRLR antagonist suggests
that endogenous, intrafollicular PRL
production actually maintains human
female frontotemporal scalp HFs in
anagen VI. These data were indepen-
dently confirmed by calculation of the
hair cycle score (Figure 1d), and by the
microarray-based demonstration that
PRL downregulated the steady-state
transcript levels for a number of cata-
gen-associated genes (Table 2).
In line with a hair-growth-promoting
effect of PRL in female frontotemporal
scalp HFs, quantitative immunohisto-
morphometry revealed increased hair
matrix keratinocyte proliferation in situ.
This was reversed by treatment with a
PRLR antagonist (Figure 1e). In fact, a
stimulatory effect of PRL on the pro-
liferation of human (epidermal) kerati-
nocytes in vitro had been previously
published in this journal (Girolomoni
et al., 1993).
HAIR GROWTH EFFECTS BY PRL:
REVISITING THE LITERATURE
These unexpected findings run contrary
to the well-documented hair-growth-
inhibitory effects of PRL in mice and
humans (Craven et al., 2001, 2006;
Foitzik et al., 2003, 2006). They re-
focus our attention on hair-growth-
modulatory effects of PRL that had been
reported in the older literature and that
cannot be easily reconciled with the
notion that PRL is an across-the-board
hair-growth inhibitor (see Table 1).
Taken together with the increasing
awareness of sexual dimorphism in the
mammalian response to defined neu-
roendocrine stimuli (e.g., Aoki et al.,
2001; Pi and Voogt, 2002; Rocha et al.,
2002; Amador-Noguez et al., 2005;
Senovilla et al., 2008), the gender-
dependent differences in the response
of human scalp HFs to estrogens
(Conrad et al., 2005; Ohnemus et al.,
2006), and the well-known para-
doxical, strictly site-dependent effects
of androgens (Randall, 2008), our
new findings (Figure 1) beg the question
of whether the response of human
HFs to PRL stimulation may actually
be highly gender and/or location
dependent.
Re-analysis of the older literature
reveals an awareness of the existence
of gender differences in the response of
the HF to PRL and hyperprolactinemia.
For example, although hirsutism can be
Table 1. Published contradictory effects of PRL on hair growth in various species, with specific reference to site and
gender
Species Gender Site Effects of PRL References
Human Male Occipital
scalp
Catagen-inducing effect, inhibition of hair growth in vitro
Decreased proliferation and upregulated apoptosis of HF
keratinocytes in vitro
Foitzik et al. (2006)
Mice Female Balb/c and
PRLR knockout
mice, both
genders
Dorsal skin Delayed hair regrowth
Differences in dorsoventral HF response to PRL
corresponded to site difference in timing of hair growth
wave in vivo.
Sex differences observed in HF behavior in PRLR
knockout mice
Craven et al. (2006)
Mice Female (including
pregnant females)
Dorsal skin Induction of premature catagen in vitro
Decreased proliferation of keratinocytes in vitro
Foitzik et al. (2003)
Mice Male and female Dorsal skin Advancement in hair replacement in PRLR-deficient
mice, more pronounced in female mice, in vivo.
PRLR-deficient mice had longer and coarser hair with
normal sexual dimorphism eliminated
Craven et al. (2001)
Sheep Rams and ewes Mid-side skin High circulating PRL and peak PRLR expression
correlated with the initiation of HF growth. PRL mRNA
downregulation preceded catagen in vivo.
Specific gender differences not examined
Nixon et al. (2002)
Sheep Ewes Left mid-side
skin
Entry of anagen wool follicles into catagen in vivo Pearson et al. (1996)
Cashmere goat Male and female
goats
PRL shown to have a stimulating effect on hair shaft
elongation of secondary HFs in vitro. In addition,
increasing PRL levels reactivate telogen HFs and induce
anagen. Keeping Cashmere goats in continuous light
(elevating concentrations of blood PRL) increased mean
fiber length
Ryder and Stephenson, 1968;
Dicks et al., 1994; Ibraheem
et al., 1994
Djungarian
hamster
Endogenous PRL found to be necessary for the
development and maintenance of summer pelage
in vivo
Duncan and Goldman (1984)
Red deer Prolactin stimulated hair growth in cultured follicles
of red deer summer coat in vivo.
Thomas et al. (1993)
Abbreviations: HF, hair follicle; PRL, prolactin; PRLR, prolactin receptor.
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a feature of hyperprolactinemia in
females (Tekin et al., 2004), males
with hyperprolactinemia usually suffer
from reduced growth of facial and/or
body hair (Buvat et al., 1985; Walsh
et al., 1994). In addition, dopaminergic
agonists, which inhibit pituitary PRL
secretion and are used to treat PRL-
secreting prolactinoma, reportedly
cause hair loss. Strikingly, out of the
14 dopamine agonist-induced hair loss
cases reported in the literature, only 1
patient was man (Grauer and Sieb,
2002; Miwa and Kondo, 2003; Katz
et al., 2006). Even in that patient,
alopecia was reported in the beard
area, and not in the scalp (Grauer and
Sieb, 2002).
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Figure 1. Effects of prolactin (PRL; 400 ngml1) on female frontotemporal hair follicles (HFs). (a) Elongation data showing PRL-mediated increase in
hair shaft elongation, partially reversed by PRL receptor (PRLR) antagonist treatment, in human female frontotemporal scalp HFs. (b) PRLR antagonist
alone caused significant inhibition of elongation after 9 culture days. (c, d) Catagen-like inducing effects of the PRLR antagonist. (c) Percentage of
HFs at different hair cycle stages after 9 days in culture. (d) Calculation of the hair cycle score. Each stage of the hair cycle was scored as follows:
anagen VI¼ 100, early catagen¼ 200, mid catagen¼300. HCS, hair cycle score. (e) PRL treatment increased hair bulb expression of the proliferation
marker Ki67 in anagen VI HFs; this was reversed by addition of PRLR antagonist. *Po0.05; **Po0.01; ***Po0.001.
Table 2. Genes related to catagen induction that appear to be
downregulated by PRL treatment of female scalp HFs
Gene Fold change P-value References
TGFBR1 1.55 0.017 Foitzik et al., (2000); Sowden et al., (2007)
TGFBR2 1.81 0.0005 Foitzik et al., (2000); Sowden et al., (2007)
TGFBR3 2.37 0.001 Foitzik et al. (2000); Sowden et al. (2007)
TAIP-2 6.06 1,75E-11 Foitzik et al. (2000); Sowden et al. (2007)
BMP2 1.83 0.00007 Blessing et al. (1993); Paus and Foitzik (2004)
BMP4 1.44 0.01 Blessing et al. (1993); Paus and Foitzik (2004)
IGFBP3 1.5 0.006 Schlake et al. (2004); Buckbinder et al. (1995)
Abbreviations: BMP, bone morphogenetic protein; IGFBP, insulin-like growth factor binding protein;
TAIP, TGF-b-induced apoptosis protein; TGFBR, transforming growth factor-b receptor.
Gene expression analysis of freshly isolated human scalp HFs (25 per group) treated with vehicle/PRL
(400 ng ml1) for 48 h. The analysis was performed using Human Whole Genome Oligo Microarray
(44K) by Miltenyi Biotech GmbH (Bergisch-Gladbach, Germany).
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Gender differences in the hair re-
sponse to PRL have also been reported
earlier in mice (Craven et al., 2001). In
PRLR knockout mice, female pelage
replacement was advanced by 4 weeks,
compared to an advancement of only 4
days in males. This led to the elimina-
tion of the normal sexual dimorphism in
murine pelage replacement (Craven
et al., 2001).
In addition, site-dependent differ-
ences in HF sensitivity to PRL, as well
as to bromocriptine treatment, were
also observed when dorsal was
compared with axillary mouse skin.
For example, bromocriptine treatment
resulted in new hair growth, in both
axillae and dorsal skin, at a younger age
than in control mice. PRL treatment
abrogated this premature hair growth
(Craven et al., 2006). Although these
differential effects were attributed to
distinct hair cycle stages, they may well
have also represented site-specific dif-
ferences in the HF response. Interest-
ingly, human skin appears to show
related site-specific differences; such
as, PRL and PRLR are expressed at the
gene and protein levels in human scalp
skin (Foitzik et al., 2006), whereas no
evidence for PRL gene transcription was
found in corporal skin (Slominski et al.,
2001).
HYPOTHESIS: PRL EFFECTS ON HAIR
GROWTH ARE GENDER AND/OR
SITE DEPENDENT
On this basis, we propose the unre-
ported hypothesis that intracutaneous
PRL effects are highly gender and/or
site dependent. Conversely, this may
be related to gender- and/or location-
dependent differences in the distribu-
tion of PRLR. This differential response
may depend on the post-receptor
signal transduction pathways that are
predominantly used by the same cell
populations in different genders/skin
locations, and/or on gender- and/or
site-specific differences in the key target
genes, whose expression is up- or
downregulated after PRLR stimulation
(Figure 2). We speculate that this can
account for diametrically opposed
functional effects of PRL and PRLR
antagonists on identical peripheral
target organs, such as the skin and its
appendages. Thus, we propose that the
distinct hair-growth-modulatory effects
of PRL in female frontotemporal (Fig-
ure 1) versus male occipital scalp HFs
(Foitzik et al., 2006) are the manifesta-
tion of gender- and/or location-depen-
dent differential responses to PRL.
To identify, characterize, and me-
chanistically dissect gender- and/or
site-specific differences in the response
of peripheral tissues to PRLR ligands
is of evident biological and clinical
importance. Not only is this needed to
adequately and more efficiently tailor
PRL-related therapeutic strategies to
each gender and/or to PRL target organs
in defined anatomical locations, but
also because the increasingly appre-
ciated adverse effects of PRL and its
antagonists in rodents and humans
(Buvat et al., 1985; Katz et al., 2006;
Harvey et al., 2008) may differ between
the genders and/or distinct tissue loca-
tions.
Furthermore, we propose that the
serum-free organ culture of human
HFs from female versus male scalp
skin, and from defined scalp skin
locations (frontotemporal vs occipital),
offers a very sensitive and instructive,
physiologically and clinically highly
relevant research tool to further dissect
the proposed gender and/or location
dependence of PRL effects on nonclas-
sical, peripheral PRL target tissues in
the human system.
POSSIBLE MECHANISMS
Drawing from the example of sexual
dimorphism in the human HF response
to estrogens (Conrad et al., 2005;
Ohnemus et al., 2006), and the recog-
nized gender differences in PRLR ex-
pression, for example, in rat brains (Pi
and Voogt, 2002), one reasonable
explanation for gender- and/or loca-
tion-dependent differences in the re-
sponse to PRL and PRL antagonists
could arise from differences in PRLR
distribution and expression level. In
fact, we had previously observed
striking differences in estrogen receptor
expression between male and female
scalp skin HFs (Conrad et al., 2005). In
addition, various isoforms of the PRLR
exist, whose stimulation exerts different
biological effects (Gadd and Clevenger,
2006). Thus, gender- and/or location-
dependent differences in the pre-
dominant PRLR isoform need to be
considered (Figure 2). The constitutive
gender difference in human daytime
serum PRL levels may ‘‘prime’’ gender-
dependent differences in PRLR expres-
sion and/or sensitivity to PRL
stimulation. Furthermore, gender- and/
or location-dependent differences in
post-receptor signaling and PRL target
genes need to be considered (Figure 2).
The previously noted major differences
in the gene expression profile induced
by 17-b-estradiol in male versus female
JAK2
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BMP -2, -4, TGFBR -1,-2,-3
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STAT1 STAT3  STAT5
MAPK
Pathway
PI3K/AKT
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PRL
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Figure 2. Possible pathways for gender- and/or site-specific responses to prolactin receptor
(PRLR)-mediated signaling. Modified after Goffin et al., 2006 and Foitzik et al., 2009.
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organ-cultured human HFs (Conrad
et al., 2005) further suggests that male
and female HFs can show distinct gene
regulation in response to the same
hormonal stimulus.
Using microarray technology, we
carried out a tentative attempt to
explore gender- and/or location-depen-
dent differences in the response of HFs
to PRL. The limited available results
suggest that these do indeed exist
(Table 3). This underscores that human
scalp HFs are indeed well suited as a
biologically and clinically highly rele-
vant, PRL-sensitive test system for
picking up differentially expressed
genes, whose transcription appears to
differ between the genders and skin
locations tested, and supports our hy-
pothesis of gender- and/or site-depen-
dent differences in the HF response to
PRL stimulation (Table 3). Although these
data evidently require quantitative con-
firmation on the mRNA and protein
levels, and reproduction in additional
human donors, they lend further sup-
port to our hypothesis of gender- and/or
site-specific differences in the effect
of PRL on an exemplary, nonclassical
peripheral human target tissue: the
scalp HF.
The effects of PRL on hair growth
have been studied in many species,
including mammals with both season-
ally dependent and independent hair
pelage replacement cycles. The see-
mingly conflicting effects reported in
the literature (Table 1) may well be
reconciled if one interprets them as
representations of site- and/or gender-
dependent HF responses to PRL. If con-
firmed, these differences will add a
fascinating new dimension to our un-
derstanding of sexual dimorphism in HF
responses to hormonal stimulation, and
highlight the need for a systematic
exploration of gender- and/or location-
specific PRL-mediated signaling in
the physiology and pathology of per-
ipheral PRL target tissues in the human
system.
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